ProCE Banner Activity

Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC

Slideset Download
Conference Coverage
Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals